SCHEMBL4569361

SCHEMBL4569361

C[C@H](Nc1ccnc2ccnn12)c1cc2cccc(Cl)c2c(N2CCN(C)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN3 Q9UGI6 1/20 0.38
HRH4 Q9H3N8 3/20 0.36
CDK2 P24941 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3R1 P27986 1/20 0.35
CNR2 P34972 2/20 0.34
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
DPP4 P27487 1/20 0.33
RAD52 P43351 2/20 0.33
S100A4 P26447 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
HTR1A P08908 1/20 0.32
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
ABL1 P00519 1/20 0.32
ALK Q9UM73 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4569342 0.79 KCNN3 (0.36) KCNN3PIK3CDPIK3R1CCNT1CDK9
SCHEMBL4569369 0.79 KCNN3 (0.36) KCNN3PIK3CDPIK3R1ABL1CYP3A4
SCHEMBL4569389 0.77 HTR2C (0.38) KCNN3PIK3CDPIK3R1CNR2CYP1A2
SCHEMBL5019549 0.76 HRH4 (0.35) HRH4CNR2SMN1; SMN2HTR1AALK
SCHEMBL4569370 0.76 KCNN3 (0.35) KCNN3PIK3CDPIK3R1CCNT1CDK9
SCHEMBL4569360 0.74 PIK3CD (0.51) HRH4PIK3CDCNR2CYP1A2CYP3A4
SCHEMBL4569424 0.74 EGFR (0.35) KCNN3CDK2PIK3CDPIK3R1CCNT1
SCHEMBL3695712 0.74 HRH4 (0.46) HRH4HTR1ACYP1A2CYP3A4CYP2D6
SCHEMBL14649252 0.74 PIK3CD (0.55) KCNN3PIK3CDPIK3R1
SCHEMBL4569383 0.73 LRRK2 (0.34) KCNN3CDK2PIK3CDPIK3R1CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388183-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2016-07-12 US disclosed
US-9388183-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2016-07-12 US disclosed
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2015-01-29 US disclosed
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2015-01-29 US disclosed
US-8901133-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-8901133-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
WO-2012064973-A2 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2012-05-18 WO disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB KCNN3 1944/4885HRH4 1854/4885CDK2 100/4885
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB KCNN3 1944/4885HRH4 1854/4885CDK2 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.